(disclaimer:no information on this thread is intended as investment advice)
Charts
(VER1405839)
News
01/12/08
07:30
TFNF
28/11/08
14:31
TFNF
26/11/08
15:54
TFNF
26/11/08
15:52
TFNF
19/11/08
16:30
UKREG
14/11/08
16:58
TFNF
Vernalis is a UK-based specialty pharmaceutical company with two marketed products, Apokyn® to treat immobilising "off" episodes in patients with advanced Parkinson's disease and Frovatriptan, to treat migraine. The company has a broad development pipeline focused on neurology and central nervous system disorders.
Product Focus
Apokyn® (apomorphine hydrochloride injection) is approved in the United States for the acute, intermittent treatment of hypomobility, "off" episodes associated with advanced Parkinson’s disease.
Frovatriptan is a selective 5-HT1B/1D receptor agonist approved in the United States and Europe as an acute oral treatment for migraine headache. Vernalis is currently conducting further trials to develop frovatriptan as the only prophylactic treatment for menstrually-related migraine (MRM).
Distinctive Characteristics
Lowest headache recurrence rates in the triptan class
Long half-life of 26 hours
Vernalis is recognised as one of Europe’s leading biotechnology companies, with a robust financial position, a marketed migraine treatment, frovatriptan, and a healthy pipeline of viable product candidates.
In 2004, Vernalis made substantial progress towards its objective of creating a sustainable, self-funding, R&Ddriven biotechnology company by building a portfolio of products focused in the areas of cancer and neurological disorders. This is being achieved by internal R&D, inlicensing and through the acquisition of, or merger with, other companies
News Expected for 2006
Frovatriptan: MRM efficacy data H1 06
Frovatriptan: MRM regulatory submission H1 06
V10153: Completion of Phase IIa in stroke H1 06
V1003: Completion of Phase IIa (Reckitt Benckiser) H1 06
V24343: Start of Phase I in obesity and related disorders H2 06
Apokyn® Half Yearly sales data H2 06
Vernalis stock quotes
Vernalis stock charts
Follow this thread
